NSRX’s Phase 2 Study: NS002 Delivers Epinephrine Twice as Fast as EpiPen® in Critical Minutes
Faster Epinephrine Delivery Sets NS002 Apart in Phase 2 Results
Nasus Pharma (NYSE:NSRX) has released positive top line results from its Phase 2 clinical trial evaluating NS002, an intranasal powder formulation designed for the emergency treatment of anaphylaxis. The standout takeaway: NS002 achieved the critical 100 pg/mL plasma epinephrine threshold in a median time of 1.69 minutes—nearly twice as fast as the widely used EpiPen®, which took 3.42 minutes (p=0.033). This rapid delivery could have major implications for treating life-threatening allergic reactions where every second matters.
Key Efficacy Metrics Highlight NS002’s Edge
Looking closer, the clinical trial of 50 healthy adults demonstrated accelerated absorption and broader effectiveness for NS002 versus EpiPen®. At the 2.5-minute mark, 67.4% of NS002 patients had reached the therapeutic threshold, compared to only 27.1% with EpiPen® (p=0.0001). By 5 minutes, 88.4% of NS002 recipients surpassed the critical marker, versus 64.6% in the comparator group (p=0.0081). At 10 minutes post-administration, nearly all NS002 subjects (about 95%) reached the threshold.
| Parameter | NS002 | EpiPen® | Significance |
|---|---|---|---|
| Median Time to 100 pg/mL (T100) | 1.69 min | 3.42 min | p=0.033 |
| % of Subjects at 2.5 min | 67.4% | 27.1% | p=0.0001 |
| % of Subjects at 5 min | 88.4% | 64.6% | p=0.0081 |
| Median Time to Peak (Tmax) | 15 min | 19.8 min | — |
| AUC, First 5–10 Minutes | ~50% higher vs. EpiPen® | Baseline | Statistically significant |
Consistent Efficacy in Repeat Dosing Scenarios
NS002’s faster absorption and higher drug exposure were maintained even with repeat dosing, whether or not patients faced nasal allergic challenges—a scenario designed to mimic real-world emergencies. This suggests reliability across a spectrum of use cases, including severe or recurrent allergic reactions that require a second dose.
Safety Remains Strong with No Serious Adverse Events
No serious adverse events were reported for NS002 in this study, supporting a favorable safety and tolerability profile. Peak plasma concentrations (Cmax) for NS002 also matched those observed for EpiPen®, adding to its clinical credibility. The product’s easy-to-use, needle-free design could further reduce barriers during emergencies.
Looking Ahead: Pivotal Study Expected in Q4 2026
With robust Phase 2 data in hand, Nasus Pharma is preparing to advance NS002 into a pivotal clinical trial, aiming for initiation in the fourth quarter of 2026. CEO Dan Teleman highlighted the product’s potential to lead in the evolving landscape of anaphylaxis treatment. For patients and providers, a faster, needle-free epinephrine option could mark a significant leap forward in emergency allergy care.
Key Takeaways for Stakeholders
NS002’s Phase 2 results offer compelling evidence for faster epinephrine delivery and consistent efficacy, backed by a solid safety profile. While forward-looking statements from the company remain subject to regulatory and research hurdles, these findings position Nasus Pharma at the frontier of next-generation anaphylaxis solutions. The upcoming pivotal trial will be a crucial milestone to watch for anyone tracking innovation in this high-stakes therapeutic space.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI